688277.SH
天智航-U
SSE · Healthcare · Medical - Instruments & Supplies · CN
CNY 15.12
−3.94%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 273.0M | 278.8M | 178.8M | 210.0M | 156.2M |
| Cost of Revenue | 90.3M | 85.8M | 53.3M | 67.6M | 53.6M |
| Gross Profit | 182.7M | 193.0M | 125.5M | 142.4M | 102.6M |
| Operating Expenses | |||||
| R&D Expense | 123.1M | 123.2M | 85.6M | 140.3M | 122.6M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 90.0M | 95.5M | 83.3M | 80.8M | 65.5M |
| Selling & Marketing Expense | 156.8M | 150.6M | 104.8M | 130.9M | 91.4M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 389.7M | 387.5M | 284.0M | 357.0M | 279.5M |
| Cost and Expenses | 480.0M | 473.3M | 337.3M | 424.6M | 333.1M |
| Operating Income (EBIT) | (187.9M) | (154.6M) | (99.3M) | (150.4M) | (143.9M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (187.8M) | (154.7M) | (99.5M) | (150.7M) | (144.2M) |
| Income Tax Expense | 44.6M | 41.4M | 21.6M | 10.6M | (31.8M) |
| Bottom Line | |||||
| Net Income | (216.0M) | (182.7M) | (121.1M) | (156.4M) | (110.6M) |
| Earnings from Cont. Ops | (232.5M) | (196.1M) | (121.1M) | (161.3M) | (112.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (216.0M) | (182.7M) | (121.1M) | (156.4M) | (110.6M) |
| Per Share | |||||
| Basic EPS | (CN¥0.47) | (CN¥0.40) | (CN¥0.27) | (CN¥0.35) | (CN¥0.26) |
| Diluted EPS | (CN¥0.47) | (CN¥0.40) | (CN¥0.27) | (CN¥0.35) | (CN¥0.26) |
| Revenue Per Share | CN¥0.59 | CN¥0.61 | CN¥0.40 | CN¥0.47 | CN¥0.37 |
| Shares | |||||
| Basic Shares Outstanding | 464.5M | 456.9M | 448.6M | 446.8M | 425.3M |
| Diluted Shares Outstanding | 464.5M | 456.9M | 448.6M | 446.8M | 425.3M |
| Profitability Metrics | |||||
| EBITDA | — | (107.5M) | (61.6M) | (122.3M) | (120.9M) |
| D&A | — | 47.2M | 37.7M | 28.1M | 23.0M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026